2022年11月17日,

CG肿瘤学,欧文的溶瘤细胞的免疫疗法公司筹集了120美元的系列E资助。圆被ORI资本共同,经度资本和Decheng资本,参与RA资本管理,Acorn Bioventures,马林公司盟友桥组和Sirona资本。与融资,布莱恩·刘,医学博士,Principal from Longitude Capital, will join the company’s board of directors. The company intends to use the funds to advance its clinical programs in bladder cancer towards FDA approval as well as broaden the scope of its pipeline to address unmet medical needs in urologic cancer, such as the first-line setting in Bacillus Calmette-Guérin (BCG)-naïve, intermediate-risk non-muscle invasive bladder cancer (NMIBC) patients. Led by CEO Arthur Kuan, CG Oncology is an oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with urologic cancer. Its lead candidate, CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. CG0070 is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO® (nivolumab). The company has secured a total of over $200M in funding to date. FinSMEs 17/11/2022